The lead candidate compounds exhibited enhanced MCT1 and cancer cell proliferation inhibition properties, led to glycolysis and mitochondrial dysfunction, and showed significant in vivo tumor growth inhibitions. Here, SLC16A1 is linked to neoplasm.